Features

Features

Trials to watch: Phase III TB vaccines and MDR-TB treatments

It has been several years since a new tuberculosis (TB) drug advanced into Phase III trials, but momentum in the…

Features

Technology a key tool in successful clinical supply management

Features

Strong relationships among stakeholders key to clinical supply chain success

Features

Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials

Features

Building for decades: Dubai’s long game in life sciences

Features

Opening clinical trials to pregnant women

Features

Women first: the Gulf’s new healthcare blueprint

Features

The clinical trial supply model of the future

Features

Podcast: Sanofi’s head of clinical supply chain operations on evolving the clinical trial supply model

Features

Podcast: Rare Disease Day: FDA guidance allowing advancement

Abigail Beaney , Robert Barrie and Frankie Fattorini

Features

Rare disease developers applaud clarity in FDA guidance

Features

The Bayesian challenge: complexity that pays off

Features

How new technologies could transform clinical trial execution

Features

Magazine: Smart and connected packaging

Features

SLE: four trials to watch in 2026

Annabel Kartal Allen

Features

Trial acceleration: AI supports progress, relationships drive success

News

Speech biomarkers offer new lease of life to patient experience and trial retention

Annabel Kartal Allen

Features

Podcast: Healthcare’s biggest 2025 trends and 2026 predictions

Features

Pharma positions itself for 2026 amid an evolving US landscape

Features

AI takes charge of data, but challenges linger

Features

APAC’s rising stars beyond China

Features

OCT DACH 2025: Geopolitics, trial equity and technology take centre stage

Annabel Kartal Allen

Features

Public sector R&D cuts could be the “silent economic killers” of US exceptionalism

Features

Multiple sclerosis: three trials to watch

Annabel Kartal Allen

Features

‘The time of the Einsteins is over’: Pharma urged to rethink trials for 2050

Features

Pharma R&D set to endure despite rising MFN costs

Features

Europe’s path to maintaining clinical trial hotbed of innovation

Features

OS endpoint focus will realign industry to “ultimate goal”

Annabel Kartal Allen

Features

Trials to watch: Three major catalysts in Alzheimer’s disease

News

What does the EU Data Act mean for businesses?

Features

From humble to global: China’s biotechs navigate the demands of international trials

Catherine Longworth

Features

Podcast: key trials and trends from ESC Congress 2025

Features

NSCLC: three trials to keep an eye on

Annabel Kartal Allen

Features

Podcast: Alternative testing models to shape toxicology “with time”

Annabel Kartal Allen

Features

China takes lead in CGT trials amid Western funding challenges

Features

Uncertainty remains over FDA block on China engineering of US cells

Features

Are concomitant medications complicating your clinical trial?

Features

Ukraine’s clinical trial surge amid war: a quiet comeback story

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close